Trial · NCT03115424
Effect of GLP-1 Receptor Agonism After Sleeve Gastrectomy
NCT03115424, Phase 3, Completed, Mayo Clinic; results first posted 2024-09-27
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effect of GLP-1 Receptor Agonism After Sleeve Gastrectomy. Trials, record NCT03115424. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03115424
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effect of GLP-1 Receptor Agonism After Sleeve Gastrectomy
- NCT number
- NCT03115424
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 46 participants, actual
- Lead sponsor
- Mayo Clinic
- Conditions
- Obesity
- Interventions
- Saxenda, Placebos, RYGB
- First posted
- 2017-04-14
- Last updated
- 2024-09-27
- Results first posted
- 2024-09-27
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Weight | baseline and 36 months | Subjects calculated weight in kilograms |
| Secondary | Systolic Blood Pressure | baseline and 36 months | Systolic blood pressure (top number of blood pressure reading) |
| Secondary | Diastolic Blood Pressure | baseline and 36 months | Diastolic blood pressure (bottom number of blood pressure reading) |
| Secondary | Low-density Lipoprotein (LDL) | baseline and 36 months | LDL's carry cholesterol through the bloodstream. LDL is called bad cholesterol because high amounts can form plaques in the blood vessels, increasing risk for heart disease. Adult normal range is less than 100 mg/dL. |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Weight | baseline and 36 months | Data was not collected nor analyzed for eight subjects in the Sleeve Gastrectomy Saxenda arm. Data was not collected nor analyzed for seven subjects in the Sleeve Gastrectomy Placebo arm. Data was not collected nor analyzed for thirteen subjects in the Roux-en-Y Gastric (RYGB). | kilograms | MEAN |
| SECONDARY | Systolic Blood Pressure | baseline and 36 months | Data was not collected nor analyzed for eight subjects in the Sleeve Gastrectomy Saxenda arm. Data was not collected nor analyzed for seven subjects in the Sleeve Gastrectomy Placebo arm. Data was not collected nor analyzed for thirteen subjects in the Roux-en-Y Gastric (RYGB). | Millimeters of Mercury | MEAN |
| SECONDARY | Diastolic Blood Pressure | baseline and 36 months | Data was not collected nor analyzed for eight subjects in the Sleeve Gastrectomy Saxenda arm. Data was not collected nor analyzed for seven subjects in the Sleeve Gastrectomy Placebo arm. Data was not collected nor analyzed for thirteen subjects in the Roux-en-Y Gastric (RYGB). | Millimeters of Mercury | MEAN |
| SECONDARY | Low-density Lipoprotein (LDL) | baseline and 36 months | Data was not collected nor analyzed for eight subjects in the Sleeve Gastrectomy Saxenda arm. Data was not collected nor analyzed for seven subjects in the Sleeve Gastrectomy Placebo arm. Data was not collected nor analyzed for thirteen subjects in the Roux-en-Y Gastric (RYGB). | mg/dL | MEAN |
Source ClinicalTrials.gov
Results by group24
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Weight | Sleeve Gastrectomy Saxenda | baseline | 127 | Standard Error 7 | kilograms |
| Weight | Sleeve Gastrectomy Placebo | baseline | 130 | Standard Error 8 | kilograms |
| Weight | Roux-en-Y Gastric (RYGB) | baseline | 126 | Standard Error 4 | kilograms |
| Weight | Sleeve Gastrectomy Saxenda | 36 months | 75 | Standard Error 8 | kilograms |
| Weight | Sleeve Gastrectomy Placebo | 36 months | 107 | Standard Error 10 | kilograms |
| Weight | Roux-en-Y Gastric (RYGB) | 36 months | 98 | Standard Error 7 | kilograms |
| Systolic Blood Pressure | Sleeve Gastrectomy Saxenda | baseline | 129 | Standard Error 4 | Millimeters of Mercury |
| Systolic Blood Pressure | Sleeve Gastrectomy Placebo | baseline | 130 | Standard Error 7 | Millimeters of Mercury |
| Systolic Blood Pressure | Roux-en-Y Gastric (RYGB) | baseline | 123 | Standard Error 4 | Millimeters of Mercury |
| Systolic Blood Pressure | Sleeve Gastrectomy Saxenda | 36 months | 112 | Standard Error 7 | Millimeters of Mercury |
1 to 10 of 24Source ClinicalTrials.gov
See all 24 results by groupParticipant flow9
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Sleeve Gastrectomy Saxenda | 12 | |
| Overall Study | STARTED | Sleeve Gastrectomy Placebo | 9 | |
| Overall Study | STARTED | Roux-en-Y Gastric (RYGB) | 25 | |
| Overall Study | COMPLETED | Sleeve Gastrectomy Saxenda | 12 | |
| Overall Study | COMPLETED | Sleeve Gastrectomy Placebo | 9 | |
| Overall Study | COMPLETED | Roux-en-Y Gastric (RYGB) | 25 | |
| Overall Study | NOT COMPLETED | Sleeve Gastrectomy Saxenda | 0 | |
| Overall Study | NOT COMPLETED | Sleeve Gastrectomy Placebo | 0 | |
| Overall Study | NOT COMPLETED | Roux-en-Y Gastric (RYGB) | 0 |
Source ClinicalTrials.gov
Adverse events12
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Hgb < 11.5 g/dL | Blood and lymphatic system disorders | Sleeve Gastrectomy Saxenda | 0 | 12 | |
| other | Hgb < 11.5 g/dL | Blood and lymphatic system disorders | Sleeve Gastrectomy Placebo | 0 | 9 | |
| other | Hgb < 11.5 g/dL | Blood and lymphatic system disorders | Roux-en-Y Gastric (RYGB) | 1 | 25 | 1 |
| other | Nausea | General disorders | Sleeve Gastrectomy Saxenda | 2 | 12 | 2 |
| other | Nausea | General disorders | Sleeve Gastrectomy Placebo | 1 | 9 | 1 |
| other | Nausea | General disorders | Roux-en-Y Gastric (RYGB) | 14 | 25 | 14 |
| other | Vomiting | General disorders | Sleeve Gastrectomy Saxenda | 2 | 12 | 2 |
| other | Vomiting | General disorders | Sleeve Gastrectomy Placebo | 1 | 9 | 1 |
| other | Vomiting | General disorders | Roux-en-Y Gastric (RYGB) | 13 | 25 | 13 |
| serious | Seizure | Nervous system disorders | Sleeve Gastrectomy Saxenda | 1 | 12 | 2 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 adverse eventsAdverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Sleeve Gastrectomy Saxenda | 0 | 12 |
| Total, all-cause mortality | Sleeve Gastrectomy Placebo | 0 | 9 |
| Total, all-cause mortality | Roux-en-Y Gastric (RYGB) | 0 | 25 |
| Total, other adverse events | Sleeve Gastrectomy Saxenda | 2 | 12 |
| Total, other adverse events | Sleeve Gastrectomy Placebo | 1 | 9 |
| Total, other adverse events | Roux-en-Y Gastric (RYGB) | 14 | 25 |
| Total, serious adverse events | Sleeve Gastrectomy Saxenda | 1 | 12 |
| Total, serious adverse events | Sleeve Gastrectomy Placebo | 0 | 9 |
| Total, serious adverse events | Roux-en-Y Gastric (RYGB) | 0 | 25 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03115424
GET https://conductscience.org/api/trials/v1/NCT03115424/results?page=2